1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Janssen/Legend’s Cilta-Cel Consistent In Earlier Myeloma, Longer-Term Results

Bristol’s Abecma Beat CAR-T To Market, Maybe Not In Second-Line

 
• By Mandy Jackson

The partners reported initial data at ASH for their BCMA-targeting CAR-T therapy in second-line multiple myeloma that appear consistent with longer-term results and ahead of their main competitor, Bristol’s Abecma.

Myeloma multiplex leukemia cancer 3d color render isometric view
Cilta-cel is closing in on the second line in multiple myeloma • Source: Alamy

Janssen Pharmaceutical Cos. and Legend Biotech Corp. are seeing similar response rates for their BCMA-targeting CAR-T therapy ciltacabtagene autoleucel (cilta-cel) in earlier multiple myeloma settings. The partners presented data at the American Society of Hematology (ASH) meeting that show response rates in multiple myeloma patients in the second through fourth lines of treatment that match the high and long-lasting responses seen in patients with much more advanced forms of the disease.

The data were revealed on 12 and 13 December, almost six weeks after Janssen, a Johnson & Johnson subsidiary, and Legend announced a three-month delay in the US Food and Drug Administration approval decision for cilta-cel in relapsed or refractory multiple myeloma, moving the action date from 28 November to 28 February. The shift gave Abecma (idecabtagene vicleucel) from Bristol Myers Squibb Company and 2seventy Bio, Inc

More from Clinical Trials

More from R&D

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

 
• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.

Lilly And Alchemab Tap Into Resilient Individuals To Develop ALS Drug

 
• By Andrew McConaghie

The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.

Pipeline Watch: Thirteen Approvals And Ten Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.